GulsumEmelPamukMD

Physician

Are you Dr. Pamuk?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.
Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, Haiyan Chen, Shwu-Luan Lee
Clinical Cancer Research. 2024-10-01
Project Confirm: Accelerated Drug Approvals for CML-Response.
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, Mel Mann, Michael J Mauro
Clinical Cancer Research. 2024-01-05
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk
Cancer Discovery. 2023-12-12